SecBot SecBot
PRESS-RELEASE ·Filed Jul 13, 2026

ERAS

Erasca, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The 57% uORR in pancreatic cancer and the accelerated registration-enabling trial plans are strong positive catalysts for ERAS. However, this is an early-stage, single-arm Phase 1 dataset with limited patients (N=7 at RDE). Monitor for additional confirmatory data, particularly the initiation of the planned Phase 3 trials and the H1 2027 data readouts.

DirectionBullish
Confidencemedium
Horizonweeks

Drugs in focus

ERAS drug pipeline →

ERAS-0015

◆ Mixed Named in this press release
Impact
Phase
Phase 1
Time to market
~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
Next catalyst
None dated

What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$19.50
T+0 close · Jul 13, 2026 · via day close
Latest settled
−27.59%
T+60 · $14.12
Vs SPY
−30.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $19.50entry
  2. T+1 · 4mo ago +9.03%α +8.63% · $21.26
  3. T+5 · 4mo ago −3.49%α −2.19% · $18.82
  4. T+20 · 3mo ago −6.10%α −8.59% · $18.31
  5. T+60 · 6w ago −27.59%α −30.97% · $14.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca reported encouraging preliminary Phase 1 data for ERAS-0015, its pan-RAS molecular glue, showing a 57% unconfirmed overall response rate (uORR) at 8 weeks in 2L+ KRAS G12X pancreatic cancer at the 32 mg QD recommended dose. The company outlined accelerated development plans including a potentially registration-enabling trial in lung cancer in H1 2027 and a Phase 3 pancreatic cancer trial in 2027, which for an early-stage biotech is a significant positive catalyst.

Key Facts

  • 57% uORR8wk in 2L+ KRAS G12X pancreatic cancer at RDE of 32 mg QD (N=7).
  • Median relative dose intensity of 100% at both 24 mg QD and 32 mg QD.
  • No DLTs observed; therapy generally well-tolerated with no discontinuations due to TRAEs.
  • First dose escalation combination cohort of ERAS-0015 (16 mg) with panitumumab cleared without DLTs.
  • Plan to initiate potentially registration-enabling trial in 2L+ NSCLC in H1 2027.
  • Plan to initiate Phase 3 pivotal trial in 1L pancreatic cancer in 2027.
  • Additional ERAS-0015 monotherapy and combination data expected in H1 2027.

Financial Impact

Early-stage biotech with no disclosed revenue; the Phase 1 update and registration-enabling plans represent a transformative pipeline catalyst for a company with a $5.8B market cap.

Risk Factors

  • Early Phase 1 data with small sample size (N=7 at RDE); response rates may change with more patients.
  • Unconfirmed responses may not all convert to confirmed partial responses.
  • Potential IP litigation with Revolution Medicines over ERAS-0015 patent infringement allegations.
  • Registration-enabling trial plans subject to FDA feedback and may be delayed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3326444

Track record

26 reports on ERAS

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026